APLS FY 2020 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$251M

Gross Profit

$226M90.0% margin

Operating Income

-$214M-85.3% margin

Net Income

-$345M-137.6% margin

EPS (Diluted)

$-4.59

Cash Flow

Operating Cash Flow

-$160M

Free Cash Flow

-$166M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$961M

Total Liabilities

$756M

Stockholders' Equity

$205M

Cash & Equivalents

$566M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$251M	$0	—
Gross Profit	$226M	-$595,449	+37986.7%
Operating Income	-$214M	-$288M	+25.8%
Net Income	-$345M	-$305M	-13.2%